The 7 most recent market catalysts affecting $NPCE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 75
Neuropace shares are trading higher after Keybanc initiated coverage on the stock with an Overweight rating and announced an $18 price target.
This headline represents a significant corporate catalyst for Neuropace. Analyst initiations with 'Overweight' ratings and specific price targets often act as strong buy signals, a…
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 65
Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18
Keybanc analyst Brett Fishbin has initiated coverage on NeuroPace (NPCE) with an 'Overweight' rating and set a price target of $18. This event is significant because new analyst co…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
NeuroPace Raises FY2026 Sales Guidance from $99.000M-$101.000M to $99.500M-$101.500M vs $99.913M Est
NeuroPace (NPCE) has updated its FY2026 sales outlook, raising the lower bound by $0.5 million and the upper bound by $0.5 million, resulting in a $0.5 million increase at the midp…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
NeuroPace Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $22.826M Beat $22.654M Estimate
NeuroPace announced its Q2 financial results, reporting a smaller loss per share and higher sales than analysts had predicted. This is significant because beating analyst estimates…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on NeuroPace, Maintains $20 Price Target
This filing discloses that HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating and maintained a $20 price target for NeuroPace. This action signals continued confiden…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 75
NeuroPace Asked To Submit Submission Issue Request By FDA For Its RNS System To Include Patients With Antiseizure Medication-Resistant Idiopathic Generalized Epilepsy; FDA Indicated PMA Supplment Not Approvable In Current Form
NeuroPace received communication from the FDA stating that its Premarket Approval Supplement, aimed at expanding the RNS System's indication to include patients with antiseizure me…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 65
Mizuho Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22
Mizuho analyst Anthony Petrone initiated coverage on NeuroPace (NPCE) with an 'Outperform' rating and a $22 price target. This event is significant for NeuroPace as it provides a p…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.